Our Latest News - BUHLMANN

BUHLMANN News

Protected: Historical Overview of Ganglioside Antibodies

There is no excerpt because this is a protected post.

Continue Reading

Neuroimmunology History

Page 5 of 13 « 1 … 3 4 5 6 7 … 13 »Sorry,You have not added any story yet References Chiba A et al. Latov N et al Ilyas, AA et al.
Continue Reading

Labsense News Fall 2019 Edition


Continue Reading

Flow CAST- Assay Overview Video

Flow CAST®: Research Use Only in the US. Not for diagnostic procedures. Health Canada License:101781 BÜHLMANN Flow CAST® and Basophil Activation (BAT): Basophil Activation Tests (BAT) have been extensively studied as in vitro functional assays and have demonstrated superior accuracy as compared to other blood tests for various allergies (1).  BÜHLMANN  provides a broad range of
Continue Reading

BUHLMANN Debriefing- EuroMedLab 2019

BÜHLMANN Educational Workshop at EuroMedLab 2019 The BÜHLMANN Educational Workshop at EuroMedLab 2019, focused on optimizing workflow for fecal calprotectin testing was a great success.  This workshop offered insightful presentations from three laboratories discussing the process of stool sample pre-analytics and how they worked to find a solution to cope with continuously increasing test numbers.
Continue Reading

BÜHLMANN fCAL® turbo Success Story- Freeman Hospital, Newcastle

The Benefits of Switching to BÜHLMANN Assay for Calprotectin Testing Dr. Elodie Hanon, Prinicpal Clinial Scientist at the Freeman Hospital, Newcastle, UK (Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories.) Highlight from this Perspective Article "We went live with the fCAL turbo in March 2018, and there really have been no issues. The turn-around time
Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for CALEX®Cap Stool Preparation Device

BÜHLMANN CALEX® Cap, a single use tube intended for the preparation of human stool samples to be used with the BÜHLMANN fCAL® turbo, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, 2019: BÜHLMANN Laboratories AG, is proud to announce it received United
Continue Reading

CALEX® Cap

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718 & K232057): FDA 510(k) cleared. For in vitro Diagnostic Use. CALEX® Cap Stool Preparation Device- for fecal Calprotectin & fecal Pancreatic Elastase The BÜHLMANN CALEX® Cap is designed to provide convenient and safe stool extraction of multiple analytes. The optimized dilution of stool sample yields maximum extraction efficiency and analyte
Continue Reading

Labsense News Summer 2019 Edition


Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® turbo Automated Calprotectin Test

BÜHLMANN fCAL® turbo, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 26, 2019: BÜHLMANN Laboratories AG, is proud to announce it received United States Food and Drug
Continue Reading